To receive this, therapy patients must have clinical features of retinal dystrophy, viable retinal cells, and biallelic pathological RPE65 gene mutations (https://www.tga.gov.au/apm-summary/luxturna). The gene discussed is RPE65; the disease is Retinal dystrophy.